Adlai Nortye (ANL) Debt Ratio (2022 - 2025)

Adlai Nortye's (ANL) quarterly Debt Ratio came in at 0.71 in Q4 2025, up 93.24% year-on-year from 0.37 in Q4 2024, and up 93.24% on a QoQ basis from 0.37 in Q4 2024.

Adlai Nortye (ANL) Debt Ratio (2022 - 2025) Analysis & Trends

Adlai Nortye (ANL) has 4 years of Debt Ratio data on file, last reported at 0.71 in Q4 2025.

  • On a quarterly basis, Debt Ratio rose 93.24% year-over-year to 0.71 in Q4 2025; TTM through Dec 2025 was 0.71, a 93.24% increase from a year earlier, with the FY2025 full-year figure at 0.71, up 93.24% from the prior year.
  • Debt Ratio for Q4 2025 stood at 0.71, up from 0.37 in the prior quarter.
  • Over the last five years, Debt Ratio for ANL reached as high as 0.71 in Q4 2025 and fell as low as 0.06 in Q4 2022.
  • Historically, Debt Ratio has averaged 0.34 across 4 years, with a median of 0.3 in 2024.
  • Across the five-year window, Debt Ratio jumped 293.02% in 2023 and jumped 58.44% in 2024, its largest moves.
  • Year by year, Debt Ratio stood at 0.06 in 2022, then soared by 293.02% to 0.23 in 2023, then soared by 58.44% to 0.37 in 2024, then surged by 93.24% to 0.71 in 2025.
  • Per Business Quant data, the three most recent Debt Ratio figures were 0.71 in Q4 2025, 0.37 in Q4 2024, and 0.23 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 1.41
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.11
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.05
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Adlai Nortye 1.27 Bn 1.26 Bn - 0.71

Historic Data

Download Data
DateValue
Dec 31, 2025 0.71
Dec 31, 2024 0.37
Dec 31, 2023 0.23
Dec 31, 2022 0.06